White paper bolsters ctDNA as potential 'early endpoint' in cancer approvals
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsProduct Lifecycle